- Home
- OSRH vs IMNN Comparison
OSRH vs IMNN Comparison
Compare OSRH & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSRH
- IMNN
- Stock Information
- Founded
- OSRH N/A
- IMNN 1982
- Country
- OSRH United States
- IMNN United States
- Employees
- OSRH N/A
- IMNN N/A
- Industry
- OSRH
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- OSRH
- IMNN Health Care
- Exchange
- OSRH Nasdaq
- IMNN Nasdaq
- Market Cap
- OSRH 11.1M
- IMNN 12.1M
- IPO Year
- OSRH N/A
- IMNN 1985
- Fundamental
- Price
- OSRH $0.70
- IMNN $5.04
- Analyst Decision
- OSRH
- IMNN Buy
- Analyst Count
- OSRH 0
- IMNN 2
- Target Price
- OSRH N/A
- IMNN $182.61
- AVG Volume (30 Days)
- OSRH 13.9M
- IMNN 55.1K
- Earning Date
- OSRH 08-14-2025
- IMNN 11-06-2025
- Dividend Yield
- OSRH N/A
- IMNN N/A
- EPS Growth
- OSRH N/A
- IMNN N/A
- EPS
- OSRH N/A
- IMNN N/A
- Revenue
- OSRH $104,735.00
- IMNN N/A
- Revenue This Year
- OSRH N/A
- IMNN N/A
- Revenue Next Year
- OSRH N/A
- IMNN N/A
- P/E Ratio
- OSRH N/A
- IMNN N/A
- Revenue Growth
- OSRH N/A
- IMNN N/A
- 52 Week Low
- OSRH $0.45
- IMNN $4.83
- 52 Week High
- OSRH $13.40
- IMNN $41.22
- Technical
- Relative Strength Index (RSI)
- OSRH 50.81
- IMNN 27.77
- Support Level
- OSRH $0.57
- IMNN $5.53
- Resistance Level
- OSRH $0.62
- IMNN $5.85
- Average True Range (ATR)
- OSRH 0.08
- IMNN 0.32
- MACD
- OSRH 0.02
- IMNN 0.02
- Stochastic Oscillator
- OSRH 44.73
- IMNN 4.57
About OSRH OSR Holdings Inc. Common Stock
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).